Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intravenous esketamine for treatment-resistant depression
2011-005992-17Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2012
- Modality
- Small Molecules, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of esketamine, Keyzilen in major depressive disorder (MDD), sponsored by Janssen Pharmaceutical. Started Mar 2012; status: completed.
02
Drugs
esketamineKeyzilen
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2011-005992-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-005992-17.